Accueil > Actualité
Actualite financiere : Actualite bourse

Novo Nordisk: growth hormone shows comparable efficacy

(CercleFinance.com) - Novo Nordisk said that a phase 2 trial has showed that its experimental drug to treat children with growth hormone deficiency was as safe and effective as its currently available treatment.


The novel growth hormone derivative - which is being developed as a once-weekly treatment option - demonstrated comparable efficacy, safety and tolerability to once-daily injections of Novo's Norditropin after one year, with improved efficacy seen at the highest dose.

The 1-year results found that mean standard deviation annualised height velocity was statistically significantly higher with somapacitan compared to daily somatropin.

Copyright (c) 2019 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.